Cryopyrin associated periodic syndromes

From WikiMD's WELLNESSPEDIA

Other Names[edit]

CAPS; Cryopyrinopathy

Autosomal dominant pedigree

Clinical features[edit]

  • Cryopyrin-associated periodic syndrome (CAPS) is a rare hereditary inflammatory disorder.
  • Clinical features include cutaneous, neurological, ophthalmologic, and rheumatologic manifestations.

Signs and symptoms[edit]

Most common symptoms include fever, fatigue, malaise, mood disorders or failure to thrive, urticarial or maculopapular rash, myalgia, arthralgia, and/or arthritis, joint contracture, patellar overgrowth, bone deformity, bone erosion and/or osteolytic lesion, conjunctivitis and/or uveitis, optic nerve atrophy, cataract, glaucoma or impaired vision, neurosensory hearing loss, morning headache, papilloedema, and/or meningitis, seizure, hydrocephalus or mental retardation and amyloidosis.

Types[edit]

It has thee types:

  1. Familial cold autoinflammatory syndrome,
  2. Muckle-Wells syndrome, and
  3. Neonatal-onset multisystem inflammatory disease.

Cause[edit]

  • CAPS results from a gain-of-function mutation of the NLRP3 gene coding for cryopyrin, which forms intracellular protein complexes known as inflammasomes.
  • Defects of the inflammasomes lead to overproduction of interleukin-1, resulting in inflammatory symptoms seen in CAPS.

Inheritance[edit]

It is a genetic disease transmitted in an autosomal dominant manner.

Diagnosis[edit]

Diagnosis is often delayed and requires a thorough review of clinical symptoms.

Treatment[edit]

  • In February 2008, rilonacept (Arcalyst) was approved for treatment of cryopyrin-assisted periodic syndromes (CAPS).
  • In June 2009, canakinumab (Ilaris) was approved for the treatment of cryopyrin-associated periodic syndromes (CAPS), in adults and children 4 years of age and older.
  • Canakinumab is manufactured by Novartis Pharmaceuticals Corporation under brand name Ilaris.
  • In May 2013, Ilaris was also approved for the treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 through 16 years.

NIH genetic and rare disease info[edit]

Cryopyrin associated periodic syndromes is a rare disease.


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Medical weight loss NYC | Affordable GLP-1 injections NYC | Budget GLP-1 weight loss shots Philadelphia | New Jersey medical weight loss | NYC medical weight loss | Philadelphia medical weight loss | Sleep clinic NYC | W8MD's Philadelphia GLP-1 doctor | Weight loss prescriptions NYC

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.